Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Grieger KD, Sayes C, Hendron CO, Rothrock G, Mansfield C, Jayanty RKM, Ensor D. Finding the key to responsible nanomaterial development. Ehs Today: The Magazine For Environment, Health And Safety Leaders. 2013 Dec 6.
Coon CD, Bokowy KL, Horblyuk R, Zisman RS, McLeod LD, Brown MT. The development and initial assessment of the strategy and leadership systems capability evaluation survey. Health Care Manag (Frederick). 2012 Oct 1;31(4):332-41.